Status:
COMPLETED
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Anesthesia, General
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary purpose of the study is to determine the time-course of recovery to a T4/T1 ratio of 0.9 within 4 minutes after 4.0 mg.kg\^-1 Sugammadex is administered at least 15 minutes after the last ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- American Society of Anesthesiologists (ASA) Class 1-3 participants who are scheduled to undergo an elective surgical procedure under general anesthesia requiring neuromuscular relaxation with the use of rocuronium.
- Exclusion criteria:
- Participants with neuromuscular disorders, significant renal dysfunction, malignant hyperthermia, allergy to medications used in general anesthesia and in whom difficult intubation is expected.
- Participants taking medications known to interfere with neuromuscular blocking agents.
- Participants who are of child-bearing potential, pregnant, and breast feeding
Exclusion
Key Trial Info
Start Date :
October 27 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 22 2006
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT00298831
Start Date
October 27 2005
End Date
May 22 2006
Last Update
March 27 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.